379 related articles for article (PubMed ID: 9418339)
21. [Dirithromycin, a new antibiotic in the treatment of pharyngeal inflammation].
Riazantsev SV; Kosenko VA; Vlasova VV; Volkova VV
Vestn Otorinolaringol; 1995; (5):40-3. PubMed ID: 7502454
[TBL] [Abstract][Full Text] [Related]
22. [Antibiotic sensitivity of Streptococcus pyogenes in pediatrics].
Gené A; González-Cuevas A; Juncosa T; Luaces C; Latorre C
Enferm Infecc Microbiol Clin; 1998; 16(6):272-4. PubMed ID: 9763744
[TBL] [Abstract][Full Text] [Related]
23. Erythromycin-resistant genes in group A β-haemolytic Streptococci in Chengdu, Southwestern China.
Zhou W; Jiang YM; Wang HJ; Kuang LH; Hu ZQ; Shi H; Shu M; Wa CM
Indian J Med Microbiol; 2014; 32(3):290-3. PubMed ID: 25008823
[TBL] [Abstract][Full Text] [Related]
24. Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel.
Weiss I; Gorodnitzky Z; Korenman Z; Yagupsky P
Eur J Clin Microbiol Infect Dis; 1997 Jan; 16(1):20-3. PubMed ID: 9063669
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program.
Gracia M; Díaz C; Coronel P; Gimeno M; García-Rodas R; Rodríguez-Cerrato V; del Prado G; Huelves L; Ruiz V; Naves PF; Ponte MC; Granizo JJ; Soriano F
Diagn Microbiol Infect Dis; 2009 May; 64(1):52-6. PubMed ID: 19232860
[TBL] [Abstract][Full Text] [Related]
26. [Streptococcus pyogenes: penicillin and erythromycin susceptibility in the cities of Neuquen and Cipolletti].
Soriano SV; Brasili S; Saiz M; Carranza C; Vidal P; Calderón J; Lopardo HA
Medicina (B Aires); 2000; 60(4):487-90. PubMed ID: 11188957
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the degree of susceptibility of Streptococcus pyogenes erythromycin-resistant strains to rokitamycin (a 16-membered macrolide) using the Epsilometer test.
Crotti D; Rossetti R; Braga PC
Drugs Exp Clin Res; 2004; 30(1):17-26. PubMed ID: 15134387
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
Schlegel L; Merad B; Rostane H; Broc V; Bouvet A
Clin Microbiol Infect; 2001 Jul; 7(7):362-6. PubMed ID: 11531981
[TBL] [Abstract][Full Text] [Related]
30. [Streptococcus pyogenes and resistance to macrolides: experience at Monza].
Minerva Pediatr; 1998; 50(1-2):XII-XIII. PubMed ID: 9658791
[No Abstract] [Full Text] [Related]
31. [Resistance to macrolides in Streptococcus pyogenes].
Bellido JL; García-Sáenz JA; Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
Rev Esp Quimioter; 1998 Sep; 11(3):196-204. PubMed ID: 9795305
[No Abstract] [Full Text] [Related]
32. [Erythromycin resistance of group A beta-hemolytic streptococci isolated from patients with upper respiratory tract infections].
Yazgi H; Ertek M; Aktaş AE
Mikrobiyol Bul; 2002 Jan; 36(1):11-4. PubMed ID: 12476761
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections.
Ikebe T; Hirasawa K; Suzuki R; Isobe J; Tanaka D; Katsukawa C; Kawahara R; Tomita M; Ogata K; Endoh M; Okuno R; Watanabe H
Antimicrob Agents Chemother; 2005 Feb; 49(2):788-90. PubMed ID: 15673769
[TBL] [Abstract][Full Text] [Related]
34. Erythromycin-resistant Streptococcus pyogenes in Argentina.
Lopardo HA; Hernandez C; Vidal P; Vazquez M; Rosaenz L; Rubinstein G; Smayevsky J; Tokumoto M; Fernandez Lausi A; Daher O; Kaufman S; Soriano SV; Brasili S; Bottiglieri M; Carranza MC
Medicina (B Aires); 2004; 64(2):143-5. PubMed ID: 15628302
[TBL] [Abstract][Full Text] [Related]
35. Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics.
Sauermann R; Gattringer R; Graninger W; Buxbaum A; Georgopoulos A
J Antimicrob Chemother; 2003 Jan; 51(1):53-7. PubMed ID: 12493787
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis.
Norrby SR; Quinn J; Rangaraju M; Leroy B
Clin Microbiol Infect; 2004 Jul; 10(7):615-23. PubMed ID: 15214873
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
38. [Phenotypic characterization of erythromycin resistance in strains of the genus Streptococcus isolated from clinical specimens].
Limia A; Jiménez ML; Delgado T; Sánchez I; López S; López-Brea M
Rev Esp Quimioter; 1998 Sep; 11(3):216-20. PubMed ID: 9795307
[TBL] [Abstract][Full Text] [Related]
39. Group A streptococci: evaluation of in vitro resistance to two macrolides.
Millesimo M; Savoia D
Microbios; 1995; 82(332):141-7. PubMed ID: 7630322
[TBL] [Abstract][Full Text] [Related]
40. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.
Klugman KP; Capper T; Widdowson CA; Koornhof HJ; Moser W
J Antimicrob Chemother; 1998 Dec; 42(6):729-34. PubMed ID: 10052895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
